Acquired von Willebrand's disease in the myeloproliferative syndrome.
An acquired hemorrhagic disorder developed in two patients in association with postsplenectomy thrombocytosis and leukocytosis during the course of the myeloproliferative syndrome. The presence of acquired von Willebrand's disease in these individuals was demonstrated by a decrease or absence of the larger von Willebrand factor (vWF) multimers, alteration of the repeating vWF multimeric "triplet," decreased ristocetin cofactor activity (vWF:RCo), and prolonged bleeding time. The bleeding stopped in both patients after treatment with either 1-deamino-[8-D-arginine]-vasopressin (DDAVP) or Cohn fraction I. Treatment with thrombocytapheresis and azathioprine or busulfan resulted in reduction of the elevated platelet and white cell counts and was associated with partial correction of the vWF abnormalities and remission of the hemostatic abnormalities. In five additional patients with the myeloproliferative syndrome, but without bleeding symptoms, large multimers of plasma vWF were diminished also. These findings suggest that acquired von Willebrand's disease should be considered when a bleeding diathesis develops during the course of the myeloproliferative syndrome.
D000328:Adult; D001760:Bleeding Time; D001798:Blood Proteins / Q000627:therapeutic use; D003894:Deamino Arginine Vasopressin / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D009196:Myeloproliferative Disorders / Q000150:complications*; D011183:Postoperative Complications; D013156:Splenectomy; D014842:von Willebrand Diseases / Q000150:complications* / Q000188:drug therapy; D014841:von Willebrand Factor / Q000032:analysis
D001798:Blood Proteins; D014841:von Willebrand Factor; D003894:Deamino Arginine Vasopressin